A GHRH analogue engineered for extended half-life. Phase 1 human data confirm sustained GH and IGF-1 elevation; development was discontinued and no efficacy trials were completed.
CJC-1295 is a modified version of the natural hormone that tells the pituitary to release growth hormone. Its distinguishing feature is a chemical anchor that binds it permanently to albumin in the blood, stretching its useful life from minutes to about a week. In the published phase 1 study, single injections raised growth hormone and IGF-1 levels for days. Note that the version sold without that anchor — often labelled 'modified GRF 1-29' — behaves very differently and lasts only minutes.
CJC-1295 is a 30-amino-acid analogue of GHRH(1-29) carrying four substitutions (D-Ala2, Gln8, Ala15, Leu27) that confer resistance to DPP-4 cleavage and trypsin-like degradation, plus a C-terminal maleimidopropionic acid Drug Affinity Complex (DAC). The DAC forms a covalent thioether bond with cysteine-34 of circulating albumin in vivo, producing a bioconjugate with a half-life of roughly 6–8 days. Agonism at the GHRH receptor, a class B GPCR on pituitary somatotrophs, drives Gs-mediated cAMP elevation, PKA activation, and CREB-dependent GH gene transcription alongside acute GH secretion. Critically, the DAC form produces sustained rather than pulsatile GHRH-receptor exposure; the phase 1 data show elevated trough GH with preserved but blunted pulse architecture, a pharmacodynamic profile that differs from physiological GH secretion.
Research areas
Community-specified data
Source note: Yields 500mcg CJC and 500mcg Ipamorelin
Source note: Yields 500mcg CJC and 250mcg Ipamorelin
Source note: Yields 500mcg CJC and 500mcg Ipamorelin
Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| Single subcutaneous doses of 30, 60 or 125 µg/kg in the phase 1 ascending dose studyThe 60 and 125 µg/kg doses produced the most sustained IGF-1 elevation. This is a pharmacokinetic characterization, not a therapeutic recommendation. | Teichman et al., Journal of Clinical Endocrinology & Metabolism 2006 |
| Weekly or every-other-week administration in the multiple-dose armReflects the ~7 day half-life of the DAC form. Non-DAC material cannot be dosed on this schedule. | Teichman et al., JCEM 2006 |
Phase 1 and phase 1/2 completed with published pharmacokinetic and pharmacodynamic data. No completed efficacy trials.
Healthy adults. Mean GH concentrations rose 2–10 fold for 6 days and IGF-1 rose 1.5–3 fold for 9–11 days after a single injection.
Weekly or biweekly dosing sustained IGF-1 elevation with no serious adverse events reported over the study window.
No completed phase 2 efficacy trial. The compound was not advanced by its originator.
The DAC is the albumin-binding anchor. With it, half-life is around a week. Without it, the peptide is simply modified GRF 1-29 and clears in roughly 30 minutes. The two require completely different dosing frequencies, and the published phase 1 data apply only to the DAC form.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults
Growth hormone-releasing hormone and its analogues: significance for the field
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →